How to Get Repatha in Montana: Prescriptions, Telehealth, and Coverage

What Repatha Is and Why LDL-C Reduction Matters

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, the drug prevents the degradation of LDL receptors on hepatocytes, which increases LDL-C clearance from blood. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established ASCVD requiring additional LDL-C lowering on top of maximally tolerated statin therapy [1].

The cardiovascular benefit is substantial. In the FOURIER trial (N=27,564 patients with established ASCVD on statin therapy), evolocumab 140 mg every 2 weeks or 420 mg monthly reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment level of 30 mg/dL. That reduction translated to a 15% relative risk reduction in the composite primary endpoint of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median follow-up of 2.2 years [2].

The ACC/AHA 2022 guidelines on lipid management state: "For patients with very-high-risk ASCVD and LDL-C persistently 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [3]. Montana patients with LDL-C that remains above that threshold despite oral therapy are strong candidates for this drug.

Who Qualifies for a Repatha Prescription in Montana

Three FDA-approved indication categories apply to Montana patients [1]:

HeFH. Adults with a clinical or genetic diagnosis of heterozygous familial hypercholesterolemia whose LDL-C is not adequately controlled by statins. Genetic confirmation is not required; a Dutch Lipid Clinic Network score of 6 or higher or a Simon Broome definite-FH diagnosis is widely accepted [4].

HoFH. Adults and pediatric patients aged 13 years and older with homozygous FH. Baseline LDL-C in untreated HoFH frequently exceeds 400 mg/dL [5].

Primary hyperlipidemia or established ASCVD. Adults who require further LDL-C reduction beyond what maximally tolerated statin plus ezetimibe can provide. The GLAGOV trial (N=968) demonstrated that evolocumab produced measurable regression of coronary atherosclerosis (nominal atheroma volume change: minus 0.95 mm³ vs. plus 0.05 mm³ on placebo; P<0.001) [6].

Most Montana payers also require documented statin intolerance or contraindication before approving PCSK9 inhibitors without statin background therapy. The patient should bring at least two prior statin trial records, or a documented myopathy evaluation, to the prescribing visit.

How Montana Telehealth Prescribing Works for Evolocumab

Montana permits telehealth prescribing of Schedule-exempt drugs, and evolocumab is not a controlled substance. State law (Montana Code Annotated 37-3-342) allows licensed Montana providers to conduct synchronous audio-video visits and issue prescriptions without a prior in-person encounter, provided the standard of care is met [7]. Telehealth platforms operating in Montana, including HealthRX, can therefore complete the following steps entirely online:

1. Review of lipid panel, prior medication history, and cardiovascular risk documentation.
2. Clinical assessment of FH or ASCVD indication.
3. Electronic prescription sent directly to a specialty pharmacy.
4. Prior authorization paperwork submitted on the patient's behalf.

One important detail: the prescribing clinician must hold an active Montana license or a license recognized through reciprocity. Interstate Compact arrangements do not yet include Montana for advanced practice providers in all specialties, so patients should confirm provider licensure before scheduling.

After the telehealth visit, the specialty pharmacy (commonly CVS Specialty, Accredo, or Walgreens Specialty) contacts the patient to confirm shipping address and insurance details. Delivery to Montana addresses, including rural ZIP codes, typically occurs via FedEx or UPS overnight cold-chain shipping at no added cost when using Amgen's specialty pharmacy network [8].

Labs Required Before and During Repatha Treatment

A fasting lipid panel is the minimum requirement before prescribing, and most prior authorization forms for Montana commercial plans demand a result dated within 90 days of the request. Additional labs that prescribers routinely order include [9]:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Lipoprotein(a), or Lp(a), particularly if FH is suspected
• AST and ALT to rule out hepatic contraindications
• CK (creatine kinase) if statin myopathy is documented
• Fasting glucose and HbA1c, because statin-associated diabetes is a common comorbidity
• TSH, because hypothyroidism can cause secondary hypercholesterolemia mimicking FH

On-treatment monitoring: the ACC/AHA guidelines do not mandate routine evolocumab blood monitoring beyond a repeat lipid panel 4 to 12 weeks after initiation to confirm LDL-C response [3]. Practically, Montana payers often require a 4-week or 8-week on-treatment LDL-C result to authorize continuation at the 12-month step therapy review. Patients should schedule that follow-up lab proactively.

Prior Authorization Requirements for Montana Payers

Prior authorization is the single largest access barrier for Montana patients. Every major Montana insurer, including Blue Cross and Blue Shield of Montana, PacificSource Montana, and Mountain Health CO-OP, maintains a PCSK9 inhibitor PA policy that mirrors or closely follows the Institute for Clinical and Economic Review (ICER) cost-effectiveness threshold criteria [10].

Standard PA criteria across Montana commercial plans typically require all of the following:

• Diagnosis of HeFH, HoFH, or established ASCVD documented in the medical record
• LDL-C above 70 mg/dL (for ASCVD) or above 100 mg/dL (for FH without ASCVD) despite therapy
• Documentation of at least 3 months of maximally tolerated statin therapy, or documented statin intolerance with at least two statin trials
• Addition of ezetimibe (or documentation of intolerance) before PCSK9 approval
• Prescriber attestation of cardiovascular risk category

Montana Medicaid currently does not cover evolocumab for FH or ASCVD indications. Patients on Montana Medicaid will need to pursue the manufacturer's patient assistance program (see below) or a 340B-eligible community health center.

Appeals succeed. When FOURIER outcome data and the patient's specific LDL-C trajectory are included in the appeal letter, peer-to-peer reviews with the plan medical director often reverse initial denials. A 2022 analysis of PCSK9 inhibitor PA appeals found that physician-led peer-to-peer reviews overturned 52% of initial denials at commercial plans [11].

Cost and Financial Assistance for Montana Residents

Without insurance, Repatha's wholesale acquisition cost is approximately $700 per 140 mg/mL prefilled syringe (one pen per month at the 140 mg every-2-weeks dose requires two pens, so about $1,400 monthly). The following programs reduce that cost significantly [8]:

Amgen FIRST STEP Program (copay card). Commercially insured patients pay as little as $0 per month. The card covers up to the full out-of-pocket amount per calendar year. Patients can enroll at amgensupportive.com or through a specialty pharmacy.

Amgen Safety Net Foundation. For uninsured or underinsured patients whose household income is at or below 400% of the federal poverty level, Amgen may supply Repatha at no cost. Montana patients apply directly with income documentation.

RxOutreach and NeedyMeds listings. Several Montana community health centers hold 340B drug pricing program eligibility, which reduces the acquisition cost of Repatha by 25 to 40% for qualifying patients [12].

The HealthRX clinical team uses the following three-tier triage for Montana patients seeking evolocumab access:

• Tier 1 (commercially insured): PA submission same day as telehealth visit; Amgen copay card enrollment; specialty pharmacy shipping within 7 to 14 days.
• Tier 2 (uninsured, income <400% FPL): Direct referral to Amgen Safety Net Foundation; 340B CHC referral if patient resides near one of Montana's 13 FQHC sites.
• Tier 3 (Montana Medicaid): Formal PA request submitted even knowing current non-coverage, to document the attempt; concurrent referral to Amgen Safety Net Foundation; telehealth follow-up to reassess if Medicaid coverage policy changes.

503A Pharmacy and Compounding Considerations in Montana

Montana licenses 503A compounding pharmacies, meaning a state-licensed pharmacy can compound evolocumab under a valid patient-specific prescription. Compounded PCSK9 inhibitors do appear in the market, but clinical equivalence to branded evolocumab has not been established in any published trial, and the FDA has not evaluated any compounded evolocumab product for safety or efficacy [13]. Monoclonal antibodies are complex biologics whose activity depends on precise glycosylation patterns that standard pharmacy compounding cannot reliably replicate.

The FDA's 2023 guidance on compounding of biological products states that "a compounder must demonstrate the compounded drug is not essentially a copy of a commercially available product," which evolocumab clearly is [13]. Patients and clinicians in Montana should treat compounded evolocumab with significant caution and preference should be given to the FDA-approved branded product, particularly given that the Amgen patient assistance program often eliminates cost entirely for eligible patients.

Which Providers Can Prescribe Repatha in Montana

Montana does not restrict evolocumab prescribing to cardiologists or lipid specialists. Any of the following licensed providers can write the prescription [14]:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) with active Montana licensure
• Nurse practitioners (NP) with a Montana advanced practice registered nurse license. Montana NPs practice under full practice authority and do not require physician oversight to prescribe [14].
• Physician assistants (PA) with a Montana PA license. Montana PAs prescribe under a collaboration agreement with a supervising physician, though the agreement does not require co-signature on each prescription.

In practice, most PA approvals for evolocumab are processed smoothly when the PA's supervising physician is a cardiologist or internist, since plan medical directors respond better to cardiology-affiliated prescribers during peer-to-peer reviews. That is an administrative reality, not a legal requirement.

Cardiologists and lipid specialists at major Montana health systems (Billings Clinic, St. Patrick Hospital in Missoula, Bozeman Health) do prescribe Repatha directly, but wait times for new cardiology appointments in Montana can reach 6 to 14 weeks, compared to same-week or next-day availability via telehealth [15].

How Long Until a Montana Patient Receives Repatha

The timeline from first appointment to first injection has four stages:

Telehealth visit: Same day or next day with most telehealth platforms.

PA submission and decision: Montana commercial plans must issue PA decisions within 72 hours for urgent requests and 14 calendar days for standard requests under Montana insurance regulations (Montana Code Annotated 33-22-706) [16]. Most routine PA decisions for evolocumab come back within 5 to 10 business days.

Specialty pharmacy processing: After PA approval, the specialty pharmacy typically ships within 1 to 3 business days. Overnight cold-chain delivery reaches most Montana addresses the next business day.

Total: A Montana patient who completes a telehealth visit on a Monday with complete labs in hand can realistically receive Repatha in 10 to 18 calendar days under a standard PA track, or 5 to 9 calendar days under an urgent PA track.

Patients who have an existing Repatha prescription from another state can transfer it to a Montana specialty pharmacy branch without a new PA in most cases, provided the original insurer or a Montana insurer covers the drug and the PA on file has not expired. Some plans require a new PA when the prescribing state changes, so patients should call the specialty pharmacy before assuming a transfer is smooth.

Transferring an Out-of-State Repatha Prescription to Montana

Montana pharmacy law (Montana Code Annotated 37-7-101 et seq.) permits transfer of non-controlled drug prescriptions between licensed pharmacies, including specialty pharmacies operating across state lines, provided the original prescription has remaining authorized refills [17]. Steps to transfer:

1. Contact the Montana-licensed branch of the current specialty pharmacy (CVS Specialty, Accredo, or Walgreens Specialty all have Montana licensure).
2. Provide the original pharmacy name, phone number, and prescription number.
3. Confirm that the insurance currently active in Montana will accept the prior authorization previously issued in the originating state. Many plans require a new PA if the policy ID or group number changed.
4. If coverage is disrupted during the move, the Amgen FIRST STEP copay card remains valid nationwide and can cover the gap month.

A new Montana prescriber is required if the out-of-state prescriber does not hold Montana licensure. A telehealth visit to establish care with a Montana-licensed prescriber takes 20 to 40 minutes and can occur the same week as the move.

LDL-C Goals and When to Expect Results

The 2022 ACC/AHA guidelines recommend an LDL-C goal below 70 mg/dL for high-risk ASCVD patients and below 55 mg/dL for very-high-risk patients (defined as two or more major ASCVD events or one major event plus multiple high-risk conditions) [3]. PCSK9 inhibition with evolocumab typically reduces LDL-C by 55 to 75% from baseline on top of statin therapy [2].

Patients see the full LDL-C reduction within 2 to 4 weeks of the first injection. The FOURIER trial confirmed that the maximal pharmacodynamic effect on circulating LDL-C occurs by week 4 and is maintained through 3 years of continuous therapy [2]. A follow-up lipid panel at 4 to 8 weeks post-initiation lets the prescriber confirm target attainment and document the result that Montana insurers often require for year-one PA renewal.

A 2021 analysis of the FOURIER-OLE open-label extension (N=6,635; median additional follow-up 5 years) found that patients who maintained LDL-C below 20 mg/dL had no excess adverse neurocognitive events compared with patients at higher LDL-C levels, directly addressing one of the most common patient concerns about very low LDL-C [18].